adamdtx, Author at DTX Pharma

DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, is pleased to announce that Jeff Friedman, MD/PhD has been appointed Chief Operating Officer, effective immediately

"Jeff is a valuable addition to the DTx Pharma team. He has served as both a scientific and business advisor since the inception of DTx [...]

adamdtx2019-12-26T16:45:26-08:00May 2nd, 2018|

DTx Pharma accepted into CONNECT Springboard Accelerator Program

DTx Pharma, a RNA-based therapeutics company, announced that it has been accepted into the prestigious CONNECT mentoring program. CONNECT is a program whose graduates have [...]

adamdtx2019-12-26T16:45:18-08:00December 1st, 2017|

DTx Pharma mentioned by JNJ executive as one of the world’s 20 hottest startups following JLABs portfolio showcase

DTx Pharma, a RNA-based therapeutics company, announced that it was one of 3 companies chosen from the JLABs San Diego site to present a 3-minute [...]

adamdtx2019-12-26T16:45:14-08:00November 29th, 2017|

DTx Pharma adds Jeff Friedman, MD, PhD, Neil Gibson, PhD, and Timothy Scott, JD to Scientific Advisory Board

DTx Pharma, a RNA-based therapeutics company, announced that Jeff Friedman, Neil Gibson and Timothy Scott joined the scientific advisory board in Q3, 2017 Dr. Friedmans [...]

adamdtx2019-12-26T16:45:09-08:00November 1st, 2017|

adamdtx

About adamdtx

DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, is pleased to announce that Jeff Friedman, MD/PhD has been appointed Chief Operating Officer, effective immediately

DTx Pharma accepted into CONNECT Springboard Accelerator Program

DTx Pharma mentioned by JNJ executive as one of the world’s 20 hottest startups following JLABs portfolio showcase

DTx Pharma adds Jeff Friedman, MD, PhD, Neil Gibson, PhD, and Timothy Scott, JD to Scientific Advisory Board